Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7630706 | 0.87 | PKM (0.60) | PPARAPKMMAPTRAB9APPARG | |
| SCHEMBL2818377 | 0.86 | L3MBTL1 (0.53) | PPARAPKMMAPTRAB9APPARG | |
| SCHEMBL863227 | 0.84 | GSK3B (0.51) | GSK3BMAPTRAB9APTPN1NPC1 | |
| SCHEMBL3629717 | 0.81 | HPGDS (0.42) | PKMMAPTRAB9APARP10LMNA | |
| SCHEMBL3682169 | 0.81 | PPARG (0.39) | PPARAPPARGL3MBTL1 | |
| SCHEMBL3686163 | 0.77 | ALDH1A1 (0.44) | PPARAMAPTRAB9APPARGLMNA | |
| SCHEMBL3078638 | 0.76 | L3MBTL1 (0.43) | MAPTRAB9ALMNAL3MBTL1GAA | |
| SCHEMBL7631246 | 0.76 | MEN1 (0.41) | PPARAPKMPPARG | |
| SCHEMBL5776738 | 0.76 | MAPT (0.50) | PPARAMAPTRAB9ALMNAL3MBTL1 | |
| SCHEMBL3319281 | 0.75 | GSK3B (0.49) | GSK3BRAB9APTPN1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249418-A1 | NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2213672-A1 | NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID | Nihon Medi-Physics Co., Ltd. (JP) | 2010-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249418-A1 | NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID | APP, APBA1, C1QBP | PPARA 3895/4885GSK3B 3662/4885PKM 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.